A Prospective Study of Anti-Mullerian Hormone (AMH) As a Potential Predictor of Chemotherapy-Induced Menopause: Preliminary Results. — ASN Events
  1. Schedule
  2. Posters - Clinical research
  3. A Prospective Study of Anti-Mullerian Hormone (AMH) As a Potential Predictor of Chemotherapy-Induced Menopause: Preliminary Results.

A Prospective Study of Anti-Mullerian Hormone (AMH) As a Potential Predictor of Chemotherapy-Induced Menopause: Preliminary Results. (#183)

Jessica Miller 1 2 3 , Hilary Martin 4 , Fiona Young 1 2 , Adnan Khattak 4 , Ganessan Kichenadasse 2 , Shawgi Sukumaran 2 , David Ross 2 , Amitesh Roy 2 , Elinor Atkinson 5 , Bogda Koczwara 2
  1. Flinders Fertility Pty Ltd., Flinders Medical Centre, Bedford Park, SA, Australia
  2. Flinders Centre for Innovation in Cancer, Bedford Park, SA, Australia
  3. Department of Medical Biotechnology, Flinders University, Adelaide, SA, Australia
  4. Department of Medical Oncology, Royal Perth Hospital, Perth, WA, Australia
  5. Flinders Medical Centre, Bedford Park, SA

BACKGROUND: Anti-Mullerian hormone (AMH) is produced by activated primary follicles of the ovary and plays a role in maintaining a pool of quiescent primordial follicles. Human serum AMH concentrations correlate to primordial follicle reserve, and correlate with time of entry to menopause. Chemotherapy causes follicular pool depletion and induces premature menopause. To date, the role of AMH in predicting chemotherapy induced menopause has not been widely investigated.
OBJECTIVE: To determine the usefulness of AMH as a tool in predicting chemotherapy-induced premature menopause.
METHODS: Serum concentrations of AMH, FSH, LH & oestradiol were measured and menopausal symptoms and quality of life surveyed for oncology patients receiving chemotherapy. Statistical methods included correlation, linear regression and Analysis of Variance, where confidence intervals were set at 95% (P=<0.05).
RESULTS: Preliminary results from n=12 women are reported. AMH levels decreased after chemotherapy treatment (P=<0.05, F=7.12), often below the assay limit of detection (LOD) after initiation of treatment; Serum AMH levels declined with age (m=-0.03, R2=0.21), in line with reported levels for cancer-free women (m=-0.04, R2=0.95). Women with higher baseline AMH levels experienced a greater rate of decline than those with lower baseline AMH (m=-0.71, R2=0.47). Baseline AMH results were negatively related to increasing FSH concentrations, used in diagnosing menopause, indicating a predictive potential for AMH with the acquisition of more data (m=-0.31, R2=0.098). Women reported an increase in menopausal symptoms (R2=0.81, m=0.18) and decrease in quality of life (R2=0.21, m=-0.06) with subsequent chemotherapy cycles.
CONCLUSIONS: AMH may serve as a useful tool in predicting chemotherapy-induced menopause, although greater precision and accuracy are required through increased sample size and lower assay LOD.